

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

Immunedecon v

RRID:SCR_023869

Type: Tool

Proper Citation

Immunedecon v (RRID:SCR_023869)

Resource Information

URL: <https://github.com/omnideconv/immunedecon v>

Proper Citation: Immunedecon v (RRID:SCR_023869)

Description: Software R package for unified access to computational methods for estimating immune cell fractions from bulk RNA sequencing data.

Resource Type: data analysis software, data processing software, software application, software resource

Defining Citation: [PMID:32124323](#)

Keywords: computational methods access, estimating immune cell fractions, bulk RNA sequencing data,

Availability: Free, Available for download, Freely available

Resource Name: Immunedecon v

Resource ID: SCR_023869

License URLs: <https://github.com/omnideconv/immunedecon v/blob/master/LICENSE>

Record Creation Time: 20230725T050218+0000

Record Last Update: 20260829T182831+0000

Ratings and Alerts

No rating or validation information has been found for Immunedecon v.

No alerts have been found for Immunedecon v.

Data and Source Information

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Guercio BJ, et al. (2026) Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1434.

Bryushkova EA, et al. (2025) FCRLs and atypical transcriptional pattern in tumor infiltrating B cells from lung and renal cancer. *Frontiers in immunology*, 16, 1587088.

Cao X, et al. (2025) High Expression of Calreticulin Affected the Tumor Microenvironment and Correlated With Worse Prognosis in Patients With Triple-Negative Breast Cancer. *Journal of immunotherapy (Hagerstown, Md. : 1997)*, 48(5), 173.

Zhang XY, et al. (2025) Saliva from oral squamous cell carcinoma patients promotes tumor progression via Inflammation, stromal remodeling, and metabolic reprogramming in a mouse model. *BMC oral health*, 26(1), 16.

Lacunza E, et al. (2025) Integrative functional genomics analysis of Kaposi sarcoma cohorts. *Scientific reports*, 15(1), 35413.

Lacunza E, et al. (2025) Integrative Functional Genomics Analysis of Kaposi Sarcoma Cohorts. *Research square*.

van Santvoort M, et al. (2025) Mathematically mapping the network of cells in the tumor microenvironment. *Cell reports methods*, 5(2), 100985.

Wang M, et al. (2025) Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors. *Cancer discovery*, 15(9), 1883.

Ricker CA, et al. (2024) Historical perspective and future directions: computational science in immuno-oncology. *Journal for immunotherapy of cancer*, 12(1).

Guo Y, et al. (2024) A novel pyroptosis-related gene signature exhibits distinct immune cells infiltration landscape in Wilms' tumor. *BMC pediatrics*, 24(1), 279.

Lapiente-Santana ??, et al. (2024) Multimodal analysis unveils tumor microenvironment heterogeneity linked to immune activity and evasion. *iScience*, 27(8), 110529.

Leng D, et al. (2023) Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(19), 3986.

Zhang J, et al. (2022) A cancer-associated fibroblast gene signature predicts prognosis and therapy response in patients with pancreatic cancer. *Frontiers in oncology*, 12,

1052132.